EUVIMEDScopri EUVIMED
BeobachtungsstudieVergleichsstudieRandomisierte kontrollierte StudieOpen access

Comparative effectiveness of extended‐release naltrexone versus buprenorphine‐naloxone on treatment interruption: Comparing findings from a reanalysis of the X:BOT RCT and harmonized target trial emulation using population‐based observational data

Sara Lodi iD, Shapei Yan, Benjamin Bovell-Ammon, Paul J Christine iD, Heather E Hsu, Dana Bernson, Patricia Novo, Joshua D Lee, John Rotrosen, Jane M Liebschutz, Alexander Y Walley, Marc R Larochelle

Addiction · 2025

DOI: 10.1111/add.70040 ↗

At a glance

Beobachtungsstudie in Addiction, 2025. Written by Sara Lodi and 11 co-authors. Institution: Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA. Major MEDLINE topics: Buprenorphine, Naloxone Drug Combination, Opioid-Related Disorders, Naltrexone, Narcotic Antagonists. Cited 4 times so far (Crossref); 46 references. The full text is freely available in PubMed Central. Funded by: NIDA NIH HHS, National Institute on Drug Abuse (NIDA).

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Background and aims It is unclear if findings from randomized controlled trials (RCT) of medications for opioid use disorder apply to real‐world settings. We estimated the effectiveness of buprenorphine‐naloxone (BUP‐NX) versus extended‐release naltrexone (XR‐NTX) on treatment interruption in a RCT and an observational study based on real‐world data.

Design

Target trial emulation to harmonize the protocol and statistical analyses of X:BOT (target trial) and the observational study (observational emulation). Baseline was randomization in the target trial and medically managed opioid withdrawal (MMOW) discharge in the observational emulation. Settings X:BOT trial and Massachusetts Public Health Data Warehouse observational data (United States).

Participants

The target trial included all X:BOT participants. The observational emulation trial included MMOW discharges from January 2014 to May 2016.

Measurements

Treatment strategies were BUP‐NX versus XR‐NTX initiation within 28 days of baseline. The outcome was treatment interruption (earliest of treatment discontinuation, incarceration, MMOW readmission, death). We estimated the 24‐week risk and risk difference.

Findings

In the target trial, 94% (269/287) and 66% (187/283) of participants randomized to BUP‐NX or XR‐NTX initiated their assigned treatment within 28 days, respectively. In the observational emulation, BUP‐NX and XR‐NTX were initiated within 28 days in 9% (5209/59 076) and 3% (1813/59 076) of MMOW discharges, respectively. The adjusted 24‐week treatment interruption risks (95% confidence interval) for BUP‐NX and XR‐NTX were 68% (60%,77%) and 72% (60%,83%) in the target trial [risk difference, −4 percentage points (pp; −17 pp,11 pp)] and 82% (81%,83%) and 93% (92%,95%) in the observational emulation [risk difference,‐11 pp (−13 pp,‐10 pp)].

Conclusions

Buprenorphine‐naloxone might be superior to extended‐release naltrexone in real‐world settings where the majority of people struggle to remain on medications for opioid use disorder. Buprenorphine‐naloxone initiators had a lower risk of treatment interruption than extended‐release naltrexone initiators in an observational emulation, but similar risks in a randomized controlled trial, although confidence intervals were wide. Trial participation, study size and residual confounding may explain these differences.

Subjects

MeSH terms (MEDLINE)

Buprenorphine, Naloxone Drug CombinationOpioid-Related DisordersNaltrexoneNarcotic AntagonistsSubstance Withdrawal SyndromeOpiate Substitution TreatmentHumansMaleAdultDelayed-Action PreparationsFemaleMiddle AgedTreatment OutcomeRandomized Controlled Trials as TopicTreatment Interruption

Author keywords

buprenorphineextended‐related naltrexonemedically managed opioid withdrawalopioid use disordertarget trial emulationtrial benchmarking

Substances

Buprenorphine, Naloxone Drug CombinationNaltrexoneNarcotic AntagonistsDelayed-Action Preparations

Authors and institutions

  • Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA.
  • Section of General Internal Medicine, Department of Medicine, Boston Medical Center and Boston University School of Medicine, Boston, MA, USA.
  • Department of Pediatrics, Boston Medical Center and Boston University School of Medicine, Boston, MA, USA.
  • Massachusetts Department of Public Health, Boston, MA, USA.
  • Department of Psychiatry, New York University Grossman School of Medicine, New York, NY, USA.
  • Department of Population Health, New York University Grossman School of Medicine, New York, NY, USA.

ORCID profiles: Sara Lodi, Paul J Christine

Funding

  • NIDA NIH HHS
  • National Institute on Drug Abuse (NIDA)

Cite

APA

Lodi, S., Yan, S., Bovell-Ammon, B., Christine, P. J., Hsu, H. E., Bernson, D., Novo, P., Lee, J. D., Rotrosen, J., Liebschutz, J. M., Walley, A. Y., & Larochelle, M. R. (2025). Comparative effectiveness of extended‐release naltrexone versus buprenorphine‐naloxone on treatment interruption: Comparing findings from a reanalysis of the X:BOT RCT and harmonized target trial emulation using population‐based observational data. Addiction. https://doi.org/10.1111/add.70040

Vancouver

Lodi S, Yan S, Bovell-Ammon B, Christine PJ, Hsu HE, Bernson D, et al. Comparative effectiveness of extended‐release naltrexone versus buprenorphine‐naloxone on treatment interruption: Comparing findings from a reanalysis of the X:BOT RCT and harmonized target trial emulation using population‐based observational data. Addiction. 2025. doi:10.1111/add.70040

BibTeX
@article{Lodi2025,
  author = {Lodi, Sara and Yan, Shapei and Bovell-Ammon, Benjamin and Christine, Paul J and Hsu, Heather E and Bernson, Dana and Novo, Patricia and Lee, Joshua D and Rotrosen, John and Liebschutz, Jane M and Walley, Alexander Y and Larochelle, Marc R},
  title = {Comparative effectiveness of extended‐release naltrexone versus buprenorphine‐naloxone on treatment interruption: Comparing findings from a reanalysis of the X:BOT RCT and harmonized target trial emulation using population‐based observational data},
  journal = {Addiction},
  year = {2025},
  doi = {10.1111/add.70040}
}
Start for free →